再生医療の市場規模、シェア、成長分析：製品別、治療領域別、地域別 - 産業予測、2024年～2031年

世界の再生医療の市場規模は、2022年に95億9,000万米ドルとなり、2023年の122億米ドルから、2031年までには836億米ドルに成長し、予測期間（2024年～2031年）のCAGRは27.2％で成長する見通しです。

再生医療の主要な目的は、さまざまな原因によって失われた機能を回復させることです。加齢、病気、怪我によって損傷した組織や臓器の修復や置換、先天性異常への対処などが含まれます。従来の治療とは異なり、再生医療には回復を早めるなどの利点があります。幹細胞治療や多血小板血漿のような技術は、身体の自然治癒力を高め、損傷した組織の修復を早め、炎症や瘢痕組織の形成を抑えます。軽微な組織損傷に対する内因性幹細胞刺激やオルガノイド移植を含む新たな手法が、今後数年間の市場成長を促進すると予想されます。幹細胞生物学における最近の進歩は、再生医療に大きな影響を与えています。成体細胞から多能性幹細胞を作製したり、制御された条件下でこれらの幹細胞から微生物を培養するなどの革新は、修復や移植のための機能的なヒト組織を作製するための新たな戦略を提供しています。政府からの支援もまた、市場拡大には欠かせない要素です。欧州連合（EU）とオランダ政府は、再生医療を重要な政策関連分野として強調しています。北米では、高齢化社会の進展により、市場は活況を呈しています。米国にあるNorth Carolina Tissue Engineering and Regenerative Medicine Societyはこの分野の研究開発を積極的に推進しており、NIHやCIRMなどの機関は学術研究やトランスレーショナルリサーチに資金を提供しています。世界のヘルスケア支出の増加も市場を押し上げると予想されます。しかし、限られた情報、胚性幹細胞使用に対する倫理的懸念、高額な投資コスト、検査感度や再現性の問題といった課題は、市場の成長を妨げる可能性があります。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次・一次情報源
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主要な市場の考察

• 技術分析
• 価格分析
• バリューチェーン分析
• 市場のエコシステム
• スタートアップ分析
• PESTEL分析
• 顧客と購買基準の分析
• サプライチェーン分析
• 規制情勢
• イノベーションマトリクス
• 主要な投資分析
• 主要な成功要因
• 市場魅力度指数
• 競合の程度

再生医療市場：製品別

• 市場概要
• 細胞療法
  • 幹細胞療法
    • 細胞移植
    • 幹細胞治療製品
      • 自己免疫療法
      • 同種療法
  • 細胞ベースの免疫療法
• 遺伝子治療
• 化粧品インプラント
• 組織工学

再生医療市場：治療領域別

• 市場概要
• 腫瘍学
• 筋骨格障害
• 皮膚科・創傷ケア
• 心血管疾患
• 眼科
• 神経学
• その他

再生医療市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • イタリア
  • 英国
  • その他欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主要な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Novartis AG（Switzerland）
• Biogen（US）
• Sarepta Therapeutics, Inc.（US）
• Gilead Sciences, Inc.（US）
• Amgen, Inc.（US）
• Smith & Nephew plc.（UK）
• MEDIPOST Co., Ltd.（South Korea）
• JCR Pharmaceuticals Co., Ltd（Japan）
• Takeda Pharmaceutical Company（Japan）
• CORESTEM Inc.（South Korea）
• Orthocell Ltd.（Australia）
• Mesoblast Ltd（Australia）
• BioRestorative Therapies, Inc.（US）
• Tegoscience（South Korea）
• APAC Biotech（India）
• Shenzhen SiBiono Genetech Co., Ltd.（China）
• Aspect Biosystems（Canada）
• Athersys, Inc.（US）
• Terumo Corporation（Japan）
• Vericel Corporation（US）

Global Regenerative Medicine Market size was valued at USD 9.59 Billion in 2022 and is poised to grow from USD 12.2 Billion in 2023 to USD 83.6 Billion by 2031, growing at a CAGR of 27.2% in the forecast period (2024-2031).

The primary aim of regenerative medicine is to restore function lost due to various causes. It involves repairing or replacing tissues and organs damaged by aging, disease, or injury, and addressing congenital abnormalities. Unlike traditional treatments, regenerative medicine offers advantages such as accelerated recovery. Techniques like stem cell therapy and platelet-rich plasma enhance the body's natural healing process, speed up the repair of damaged tissues, and reduce inflammation and scar tissue formation. Emerging methods, including endogenous stem cell stimulation and organoid transplantation for minor tissue injuries, are expected to drive market growth in the coming years. Recent advancements in stem cell biology have significantly impacted regenerative medicine. Innovations such as generating pluripotent stem cells from adult cells and cultivating microorganisms from these stem cells under controlled conditions have provided new strategies for creating functional human tissue for repair and transplantation. Government support is also a crucial factor in market expansion. The European Union and the Dutch government have emphasized regenerative medicine as a key area of policy relevance. In North America, the market is thriving due to the growing aging population. The North Carolina Tissue Engineering and Regenerative Medicine Society in the U.S. is actively promoting research and development in this field, while agencies like NIH and CIRM fund academic and translational research. Increasing global healthcare spending is also expected to boost the market. However, challenges such as limited information, ethical concerns over embryonic stem cell use, high investment costs, and issues with test sensitivity and reproducibility may hinder market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Regenerative Medicine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Regenerative Medicine Market Segmental Analysis

Global regenerative medicine market is segmented based on Product, Therapeutic Category, Distribution Channel and Region. Based on Product, the market is segmented into Cell Therapy (Stem Cell Therapy {Cell Transplantations, Stem Cell Therapy Products [Autologous Therapy, Allogeneic Therapy]}, Cell-based Immunotherapy), Gene Therapy, And Tissue Engineering. Based on Therapeutic Area, the market is segmented into Oncology, Musculoskeletal Disorders, Dermatology & Wound Care, Cardiovascular Diseases, Ophthalmology, Neurology, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Regenerative Medicine Market

The increasing investment in the regenerative medicine market has spurred extensive research and development efforts, with investors backing start-ups dedicated to creating innovative treatments and products. This financial support has fostered research collaborations and mergers within the industry. Additionally, government investment plays a significant role, facilitating the development of effective treatment options for various chronic diseases, including cancer, diabetes, and kidney disease, among others.

Restraints in the Global Regenerative Medicine Market

The high cost of therapies and the absence of standardized reimbursement policies are major challenges hindering market growth. For instance, many stem cell therapies are classified as experimental or investigational, leading to limited coverage under Medicare. This often results in substantial out-of-pocket expenses for patients, as Medicare only covers FDA-approved treatments like allogeneic transplants. The lack of comprehensive insurance coverage forces patients to either pay for treatments out of pocket or seek crowdfunding, which can delay access to necessary care and stifle market expansion. Additionally, the scarcity of approved drugs for a broad range of genetic disorders, coupled with their high costs, further limits market growth and accessibility.

Market Trends of the Global Regenerative Medicine Market

A key trend in the global regenerative medicine market is the strategic acquisition of companies by major players to enhance their research and development capabilities. The market encompasses innovative products derived from living cells, proteins, enzymes, antibodies, antibody-drug conjugates (ADCs), and genetic materials, which are crucial for developing lifesaving treatments for various chronic diseases. However, translating these advanced technologies into clinical practice often reveals a gap between theoretical potential and real-world application. To address this, leading companies are increasingly turning to acquisitions to bolster their R&D efforts and advance the development of diverse clinical applications.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Start-up Analysis
• PESTEL Analysis
• Customer & Buying Criteria Analysis
• Supply Chain Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Regenerative Medicine Market by Product

• Market Overview
• Cell Therapy
  • Stem Cell Therapy
    • Cell transplantations
    • Stem cell therapy products
      • Autologous therapy
      • Allogeneic therapy
  • Cell-based Immunotherapy
• Gene Therapy
• Cosmetics Implants
• Tissue Engineering

Regenerative Medicine Market by Therapeutic Area

• Market Overview
• Oncology
• Musculoskeletal Disorders
• Dermatology & Wound Care
• Cardiovascular Diseases
• Ophthalmology
• Neurology
• Others

Regenerative Medicine Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • Italy
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sarepta Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smith & Nephew plc. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MEDIPOST Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co., Ltd (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CORESTEM Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orthocell Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mesoblast Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioRestorative Therapies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tegoscience (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• APAC Biotech (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shenzhen SiBiono Genetech Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspect Biosystems (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Athersys, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vericel Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments